Drugs / IMGN289
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01963715 | Oct 2013 → Apr 2015 | — | ImmunoGen, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2013-08-01 | AbbVie | Regulatory ImmunoGen, Inc. Announces FDA Acceptance of IND for Company's Novel EGFR-Targeting ADC, IMGN289 abbvie.com ↗ |
| 2013-04-10 | AbbVie | Results ImmunoGen, Inc. Announces Preclinical Findings with its IMGN289 Product Candidate for the Treatment of EGFR-Overexpressing Cancers abbvie.com ↗
In preclinical testing, IMGN289 was highly active against EGFR-overexpressing cancer cells, including those not dependent on EGFR signaling and those resistant to tyrosine kinase inhibitors (TKIs). |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMGN289 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01963715 ↗ |
| Route | Intravenous | “IMGN289 Administered Intravenously” NCT01963715 ↗ |